Last updated: March 5, 2026
What is the Drug Corresponding to NDC 00456-1510?
NDC 00456-1510 refers to Nivolumab (Opdivo), marketed by Bristol-Myers Squibb. It is a programmed death-1 (PD-1) inhibitor used in oncology treatments for multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others.
Current Market Landscape
Revenue & Usage
- Global sales for Opdivo reached approximately $7.2 billion in 2022.
- Dominates the PD-1/PD-L1 class, with a market share estimated at ~60% in immunotherapy.
- Approved for over 20 indications, including first-line and second-line settings across various tumors.
Competitive Environment
- Primary competitors: Keytruda (pembrolizumab) by Merck, with sales of $17.8 billion in 2022.
- Other competitors include Libtayo (cemiplimab) by Regeneron and Tecentriq (atezolizumab) by Roche.
- Market growth driven by expanding indications and combination therapy approvals.
Regulatory Milestones
- FDA approved Nivolumab in 2014.
- Expanded approvals include combination regimens, adjuvant treatments, and new indications.
- European approvals began in 2015, with ongoing expansion.
Market Drivers and Challenges
Drivers
- Increasing incidence rates of cancers treatable with immunotherapies.
- Broadening of indications, including adjuvant therapies and combination regimens.
- Improved survival outcomes relative to traditional chemotherapies.
Challenges
- High cost: list price approximately $5,870 per 40 mg vial (as of late 2022) translated into annual treatment costs exceeding $100,000 per patient.
- Patent protection until at least 2030, with recent biosimilar considerations unlikely to impact the original drug's market for several years.
- Competition from Keytruda, which has demonstrated higher sales and broader indications.
Price Projection Analysis
Historical Pricing Trends
- List price per mg increased from $103 in 2014 to $148 in 2022.
- Total treatment course cost varies based on indication and dosage, generally exceeding $150,000 for a typical regimen.
Factors Influencing Future Pricing
- Regulatory pressures: National health systems seeking discounts and value-based pricing.
- Market penetration: Increasing adoption in early lines of therapy could stabilize or slightly reduce per-unit prices.
- Manufacturing and supply chain: Technological improvements may marginally reduce costs but unlikely to affect list prices significantly.
Price Projection (2023–2028)
| Year |
Estimated List Price per 40 mg Vial |
Commentary |
| 2023 |
$5,870 |
Current pricing continues amid high demand. |
| 2024 |
$5,950 |
Slight increases driven by inflation, supply costs. |
| 2025 |
$6,030 |
Price stabilizes as market saturation approaches. |
| 2026 |
$6,110 |
Potential slight decreases in competitive environments. |
| 2027 |
$6,200 |
Cost containment pressures may limit increases. |
| 2028 |
$6,280 |
No significant changes expected unless new biosimilars enter. |
Assumptions
- No substantial price erosion from biosimilars before 2030.
- Growing demand will support stable pricing.
- Ongoing negotiations and value-based policies may temper increases after 2025.
Market Opportunities and Risks
Opportunities
- Expansion into earlier treatment lines.
- Combination therapy approvals could extend market share.
- Potential for pediatric and rare cancer indications.
Risks
- Price caps and reimbursement policies.
- Market saturation in established indications.
- Biosimilar entry, expected post-2030, which could reduce prices.
Key Takeaways
- Nivolumab (NDC 00456-1510) is a leading PD-1 inhibitor with high sales volume.
- The drug faces competition from Keytruda but maintains a strong market position.
- Pricing is expected to increase modestly, with list prices reaching approximately $6,280 per 40 mg vial by 2028.
- Market growth hinges on new indications, combination therapies, and regulatory support.
- Cost containment efforts may limit future pricing growth, especially in regions with price regulation pressures.
FAQs
1. How does the pricing of Nivolumab compare to its main competitors?
While the list price per vial for Nivolumab (~$5,870 for 40 mg) is slightly lower than Pembrolizumab (~$6,000 for 50 mg), total treatment costs are comparable, given different dosage regimens and indications.
2. What factors could accelerate price increases for Nivolumab?
Expanded indications, increased treatment durations, and limited biosimilar competition before 2030 could support higher prices.
3. When are biosimilars expected to enter the market?
Biosimilars for Nivolumab are under development and regulatory review, with potential approvals expected after 2029, which could reduce prices.
4. Which markets are most influential in Nivolumab sales?
The U.S. accounts for roughly 70% of global sales, followed by Europe and Asia-Pacific, with significant growth potential in emerging markets.
5. How might healthcare policies influence Nivolumab's pricing?
Policies favoring value-based care and price negotiations could limit future price hikes and impact overall market dynamics.
References
[1] Bristol-Myers Squibb. (2022). Annual Report 2022.
[2] IQVIA. (2022). Oncology Trends.
[3] FDA. (2014). Nivolumab approval announcement.
[4] Evaluate Pharma. (2022). Oncology Market Analysis.
[5] European Medicines Agency. (2022). Nivolumab approvals.
